While the pandemic has continued to accelerate changes to the pharma business model, other factors – healthcare consolidation, the upcoming election, passage of the IRA – are impacting all aspects of development, commercialization, and market access. In response to these market dynamics, manufacturers have been adapting their commercial approaches. But…
More than 115 biotech companies have announced layoffs this year, on track to easily surpass 2022’s numbers. While this is not a new trend, the current trajectory is concerning, as it portends more difficult times ahead for the pharmaceutical industry–already in the midst of a major upheaval. It should also…
On August 29th, the Biden Administration named the 10 drugs that will be subject to price negotiation with Medicare in the initial implementation of the Inflation Reduction Act (IRA) of 2022. Release of the list marked a milestone in a decades-long effort by Democrats to use the purchasing power of…
For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding. Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…
Long-term success in any industry requires ongoing investment to progress customer-facing capabilities and internal operations. Health insurance is no exception and – one could argue – due to often thin differences among competitors, is a side of the health care ecosystem where smart reinvestment can create the margin to win…
Companies across every industry undergo periods of adjustment, which include tapping someone new to steer the organization in a different direction. Changing out the CEO and replacing upper management teams may sometimes be necessary, but when that shift isn’t well-executed, it can exacerbate old problems and create new ones. The…
